VYOME HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
VYOME HOLDINGS, INC. (HIND) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4500.00 per share for the 6-month period ending 2025-06-30, per its 8-K filed 2025-09-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-09-02
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $1.12.
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $0.49, a 92.80% decline from fiscal 2019.
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $6.81, a 168.11% increase from fiscal 2018.
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $2.54, a 52.17% decline from fiscal 2017.
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $5.31, a 77.59% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-06-30 | $4500.00 8-K · filed 2025-09-02 | |||
| 2020-12-31 | $0.49 10-K · filed 2021-03-12 | |||
| 2020-09-30 | $0.49 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $1.12 10-Q · filed 2020-07-30 | |||
| 2020-03-31 | $1.12 10-Q · filed 2020-06-19 | |||
| 2019-12-31 | $6.81 10-K · filed 2020-02-27 | |||
| 2018-12-31 | $2.54 10-K · filed 2019-02-22 | |||
| 2017-12-31 | $5.31 10-K · filed 2018-03-05 | |||
| 2016-12-31 | $2.99 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |